TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA Stock
Certificat
DE000SU0YUN4
| Delayed Deutsche Boerse AG 05:38:27 2024-05-21 am EDT | ||
| 9.33 EUR | -1.48% |
|
| Current month | -0.94% | ||
| 1 month | -11.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 9.33 | -1.48% |
| 24-05-20 | 9.47 | +0.32% |
| 24-05-17 | 9.44 | +0.75% |
| 24-05-16 | 9.37 | +0.54% |
| 24-05-15 | 9.32 | +1.86% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 05:38 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU0YUN |
| ISIN | DE000SU0YUN4 |
| Date issued | 2023-10-20 |
| Strike | 20,165 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 11.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.68 € |
|---|---|
| Lowest since issue | 9.06 € |
| Spread | 0.01 € |
| Spread % | 0.11% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
168.1
USD
Spread / Average Target
+9.41%
- Stock Market
- Certificates
- Certificat